Advanced in Schnitzler Syndrome

Dr. Peter D. Byeff

Hematology Oncology | Hematology | Oncology
The Hospital Of Central Connecticut At New Britain General And Bradley
81 Meriden Ave, 
Southington, CT 
Advanced in Schnitzler Syndrome
The Hospital Of Central Connecticut At New Britain General And Bradley
81 Meriden Ave, 
Southington, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Peter Byeff is a Hematologist Oncology specialist and a Hematologist in Southington, Connecticut. Dr. Byeff is rated as an Advanced provider by MediFind in the treatment of Schnitzler Syndrome. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
The Hospital Of Central Connecticut
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

THE HOSPITAL OF CENTRAL CONNECTICUT AT NEW BRITAIN GENERAL AND BRADLEY
81 Meriden Ave, Southington, CT 06489
Other Locations
THE HOSPITAL OF CENTRAL CONNECTICUT AT NEW BRITAIN GENERAL AND BRADLEY
183 N Mountain Rd, Fl 2, New Britain, CT 06053
THE HOSPITAL OF CENTRAL CONNECTICUT AT NEW BRITAIN GENERAL AND BRADLEY
100 Grand St, New Britain, CT 06052

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

1 Total Publications

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Journal: Leukemia & lymphoma
Published: April 10, 2020
Similar Doctors
Distinguished in Schnitzler Syndrome
Dr. Terri L. Parker
Hematology Oncology | Hematology | Oncology
Distinguished in Schnitzler Syndrome
Dr. Terri L. Parker
Hematology Oncology | Hematology | Oncology

Yale University

800 Howard Ave, 
New Haven, CT 
 (20.5 miles away)
203-785-2140
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Terri Parker is a Hematologist Oncology specialist and a Hematologist in New Haven, Connecticut. Dr. Parker is rated as a Distinguished provider by MediFind in the treatment of Schnitzler Syndrome. Her top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, Schnitzler Syndrome, Smoldering Multiple Myeloma, and Bone Marrow Aspiration.

Distinguished in Schnitzler Syndrome
Dr. Joshua P. Raff
Hematology Oncology | Hematology | Oncology
Distinguished in Schnitzler Syndrome
Dr. Joshua P. Raff
Hematology Oncology | Hematology | Oncology

White Plains Physician Services PC

2 Longview Ave, Fl 2, 
White Plains, NY 
 (60.7 miles away)
914-849-7600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Raff is a Hematologist Oncology specialist and a Hematologist in White Plains, New York. Dr. Raff is rated as a Distinguished provider by MediFind in the treatment of Schnitzler Syndrome. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Chronic Lymphocytic Leukemia (CLL), and Colorectal Cancer.

Distinguished in Schnitzler Syndrome
Dr. Natalia Neparidze
Hematology | Oncology | Hematology Oncology
Distinguished in Schnitzler Syndrome
Dr. Natalia Neparidze
Hematology | Oncology | Hematology Oncology

Yale University

20 York St, 
New Haven, CT 
 (20.3 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Natalia Neparidze is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Neparidze is rated as a Distinguished provider by MediFind in the treatment of Schnitzler Syndrome. Her top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byeff's expertise for a condition
ConditionClose
    View All 30 Advanced Conditions
    View All 148 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile